Disciplined Growth Investors Inc. MN Has $499,000 Holdings in Cara Therapeutics, Inc. (NASDAQ:CARA)

Disciplined Growth Investors Inc. MN boosted its stake in Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,935,718 shares of the biopharmaceutical company’s stock after purchasing an additional 120,660 shares during the period. Disciplined Growth Investors Inc. MN’s holdings in Cara Therapeutics were worth $499,000 at the end of the most recent reporting period.

Separately, Marquette Asset Management LLC acquired a new position in Cara Therapeutics during the 1st quarter worth about $86,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Stock Performance

Cara Therapeutics stock opened at $0.31 on Friday. The stock’s 50 day moving average price is $0.33 and its two-hundred day moving average price is $0.53. The stock has a market capitalization of $16.68 million, a price-to-earnings ratio of -0.14 and a beta of 0.70. Cara Therapeutics, Inc. has a 52-week low of $0.24 and a 52-week high of $1.74.

Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.10). Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. The company had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. On average, equities research analysts forecast that Cara Therapeutics, Inc. will post -1.24 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on CARA shares. Canaccord Genuity Group reissued a “hold” rating and issued a $1.00 price target (down previously from $10.00) on shares of Cara Therapeutics in a research note on Thursday, June 13th. StockNews.com assumed coverage on shares of Cara Therapeutics in a research report on Thursday. They set a “sell” rating for the company. Needham & Company LLC lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, June 13th. HC Wainwright cut shares of Cara Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, June 13th. Finally, Canaccord Genuity Group lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $10.00 to $1.00 in a report on Thursday, June 13th. One analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $2.32.

Cara Therapeutics Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.